Expanded and armed natural killer cells for cancer treatment

Cytotherapy

Volumn 18, Issue 11, 2016, Pages 1422-1434

  Shimasaki, Noriko ^a   Coustan Smith, Elaine ^a   Kamiya, Takahiro ^a   Campana, Dario ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cell therapy; chimeric antigen receptors; immunotherapy; NK cells; NKG2D

Indexed keywords

ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; MESSENGER RNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; APHERESIS; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL EXPANSION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); ELECTROPORATION; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; IN VIVO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; ADOPTIVE IMMUNOTHERAPY; ANIMAL; GENETIC ENGINEERING; IMMUNOLOGY; NEOPLASMS;

ANIMALS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 84993969535     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.06.013     Document Type: Review

References (92)

1. [1] Morvan, M.G., Lanier, L.L., NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16:1 (2015), 7–19.
2. [2] Vivier, E., Raulet, D.H., Moretta, A., Caligiuri, M.A., Zitvogel, L., Lanier, L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 331:6013 (2011), 44–49.
3. [3] Chang, Y.H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K., Campana, D., A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73:6 (2013), 1777–1786.
4. [4] Orange, J.S., Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8:9 (2008), 713–725.
5. [5] Lanier, L.L., Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:5 (2008), 495–502.
6. [6] Martinet, L., Smyth, M.J., Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 15:4 (2015), 243–254.
7. [7] Gasser, S., Raulet, D.H., Activation and self-tolerance of natural killer cells. Immunol Rev 214 (2006), 130–142.
8. [8] Ferris, R.L., Jaffee, E.M., Ferrone, S., Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28:28 (2010), 4390–4399.
9. [9] Comans-Bitter, W.M., de Groot, R., van den Beemd, R., Neijens, H.J., Hop, W.C., Groeneveld, K., et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 130:3 (1997), 388–393.
10. [10] Knorr, D.A., Bachanova, V., Verneris, M.R., Miller, J.S., Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 26:2 (2014), 161–172.
11. [11] Kim, S., Poursine-Laurent, J., Truscott, S.M., Lybarger, L., Song, Y.J., Yang, L., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:7051 (2005), 709–713.
12. [12] Fernandez, N.C., Treiner, E., Vance, R.E., Jamieson, A.M., Lemieux, S., Raulet, D.H., A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105:11 (2005), 4416–4423.
13. [13] Raulet, D.H., Vance, R.E., Self-tolerance of natural killer cells. Nat Rev Immunol 6:7 (2006), 520–531.
14. [14] Elliott, J.M., Yokoyama, W.M., Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 32:8 (2011), 364–372.
15. [15] Cooley, S., Xiao, F., Pitt, M., Gleason, M., McCullar, V., Bergemann, T.L., et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110:2 (2007), 578–586.
16. [16] Imai, C., Iwamoto, S., Campana, D., Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106 (2005), 376–383.
17. [17] Wang, W., Erbe, A.K., Hank, J.A., Morris, Z.S., Sondel, P.M., NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol, 6, 2015, 368.
18. [18] Lanier, L.L., Le, A.M., Civin, C.I., Loken, M.R., Phillips, J.H., The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:12 (1986), 4480–4486.
19. [19] Lanier, L.L., Testi, R., Bindl, J., Phillips, J.H., Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169:6 (1989), 2233–2238.
20. [20] Delahaye, N.F., Rusakiewicz, S., Martins, I., Menard, C., Roux, S., Lyonnet, L., et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17:6 (2011), 700–707.
21. [21] Semeraro, M., Rusakiewicz, S., Zitvogel, L., Kroemer, G., Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. Oncoimmunology, 4(11), 2015, e1042202.
22. [22] Albertsson, P.A., Basse, P.H., Hokland, M., Goldfarb, R.H., Nagelkerke, J.F., Nannmark, U., et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24:11 (2003), 603–609.
23. [23] Groh, V., Wu, J., Yee, C., Spies, T., Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:6908 (2002), 734–738.
24. [24] Salih, H.R., Rammensee, H.G., Steinle, A., Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:8 (2002), 4098–4102.
25. [25] Crane, C.A., Austgen, K., Haberthur, K., Hofmann, C., Moyes, K.W., Avanesyan, L., et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci USA 111:35 (2014), 12823–12828.
26. [26] Cerboni, C., Mousavi-Jazi, M., Wakiguchi, H., Carbone, E., Karre, K., Soderstrom, K., Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol 31:10 (2001), 2926–2935.
27. [27] Malmberg, K.J., Levitsky, V., Norell, H., de Matos, C.T., Carlsten, M., Schedvins, K., et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110:10 (2002), 1515–1523.
28. [28] Borrego, F., Kabat, J., Kim, D.K., Lieto, L., Maasho, K., Pena, J., et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 38:9 (2002), 637–660.
29. [29] Wilson, E.B., El-Jawhari, J.J., Neilson, A.L., Hall, G.D., Melcher, A.A., Meade, J.L., et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE, 6(9), 2011, e22842.
30. [30] Viel, S., Marcais, A., Guimaraes, F.S., Loftus, R., Rabilloud, J., Grau, M., et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal, 9(415), 2016, ra19.
31. [31] Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:5562 (2002), 2097–2100.
32. [32] Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., Frumento, G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:3 (2003), 814–819.
33. [33] Leung, W., Iyengar, R., Turner, V., Lang, P., Bader, P., Conn, P., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172:1 (2004), 644–650.
34. [34] Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Pinto, C., Heller, G., Arkun, K., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:12 (2005), 4878–4884.
35. [35] Cooley, S., Weisdorf, D.J., Guethlein, L.A., Klein, J.P., Wang, T., Le, C.T., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116:14 (2010), 2411–2419.
36. [36] Miller, J.S., Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program 2013 (2013), 247–253.
37. [37] Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 105 (2005), 3051–3057.
38. [38] Iyengar, R., Handgretinger, R., Babarin-Dorner, A., Leimig, T., Otto, M., Geiger, T.L., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5:6 (2003), 479–484.
39. [39] Lee, D.A., Verneris, M.R., Campana, D., Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol 651 (2010), 61–77.
40. [40] Tomchuck, S.L., Leung, W.H., Dallas, M.H., Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture. Biol Blood Marrow Transplant 21:1 (2015), 39–49.
41. [41] Hermanson, D.L., Bendzick, L., Pribyl, L., McCullar, V., Vogel, R.I., Miller, J.S., et al. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells 34:1 (2016), 93–101.
42. [42] James, A.M., Hsu, H.T., Dongre, P., Uzel, G., Mace, E.M., Banerjee, P.P., et al. Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling. Blood 121:14 (2013), 2627–2637.
43. [43] Romee, R., Schneider, S.E., Leong, J.W., Chase, J.M., Keppel, C.R., Sullivan, R.P., et al. Cytokine activation induces human memory-like NK cells. Blood 120:24 (2012), 4751–4760.
44. [44] Ni, J., Miller, M., Stojanovic, A., Garbi, N., Cerwenka, A., Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 209:13 (2012), 2351–2365.
45. [45] London, L., Perussia, B., Trinchieri, G., Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol 137:12 (1986), 3845–3854.
46. [46] Alici, E., Sutlu, T., Bjorkstrand, B., Gilljam, M., Stellan, B., Nahi, H., et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111:6 (2008), 3155–3162.
47. [47] Satwani, P., van de Ven, C., Ayello, J., Cairo, D., Simpson, L.L., Baxi, L., et al. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function. Cytotherapy 13:6 (2011), 730–738.
48. [48] Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:9 (2009), 4010–4017.
49. [49] Berg, M., Lundqvist, A., McCoy, P. Jr, Samsel, L., Fan, Y., Tawab, A., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11:3 (2009), 341–355.
50. [50] Harada, H., Watanabe, S., Saijo, K., Ishiwata, I., Ohno, T., A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp Hematol 32:7 (2004), 614–621.
51. [51] Kottaridis, P.D., North, J., Tsirogianni, M., Marden, C., Samuel, E.R., Jide-Banwo, S., et al. Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase i trial. PLoS ONE, 10(6), 2015, e0123416.
52. [52] Phillips, J.H., Lanier, L.L., A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562. J Exp Med 161:6 (1985), 1464–1482.
53. [53] Kobayashi, H., Dubois, S., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T.A., et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:2 (2005), 721–727.
54. [54] Melero, I., Johnston, J.V., Shufford, W.W., Mittler, R.S., Chen, L., NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190:2 (1998), 167–172.
55. [55] Fujisaki, H., Kakuda, H., Imai, C., Mullighan, C.G., Campana, D., Replicative potential of human natural killer cells. Br J Haematol 145:5 (2009), 606–613.
56. [56] Lapteva, N., Durett, A.G., Sun, J., Rollins, L.A., Huye, L.L., Fang, J., et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 14:9 (2012), 1131–1143.
57. [57] Suhoski, M.M., Golovina, T.N., Aqui, N.A., Tai, V.C., Varela-Rohena, A., Milone, M.C., et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 15:5 (2007), 981–988.
58. [58] Zhang, H., Cui, Y., Voong, N., Sabatino, M., Stroncek, D.F., Morisot, S., et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother 34:2 (2011), 187–195.
59. [59] Shah, N.N., Baird, K., Delbrook, C.P., Fleisher, T.A., Kohler, M.E., Rampertaap, S., et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood 125:5 (2015), 784–792.
60. [60] Denman, C.J., Senyukov, V.V., Somanchi, S.S., Phatarpekar, P.V., Kopp, L.M., Johnson, J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE, 7(1), 2012, e30264.
61. [61] Tam, Y.K., Martinson, J.A., Doligosa, K., Klingemann, H.G., Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5:3 (2003), 259–272.
62. [62] Cho, D., Shook, D.R., Shimasaki, N., Chang, Y.H., Fujisaki, H., Campana, D., Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16:15 (2010), 3901–3909.
63. [63] Mimura, K., Kamiya, T., Shiraishi, K., Kua, L.F., Shabbir, A., So, J., et al. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer 135:6 (2014), 1390–1398.
64. [64] Kamiya, T., Chang, Y.H., Campana, D., Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer Immunol Res 4:7 (2016), 574–581.
65. [65] Ho, E.L., Heusel, J.W., Brown, M.G., Matsumoto, K., Scalzo, A.A., Yokoyama, W.M., Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci USA 95:11 (1998), 6320–6325.
66. [66] Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:5428 (1999), 727–729.
67. [67] Gasser, S., Orsulic, S., Brown, E.J., Raulet, D.H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:7054 (2005), 1186–1190.
68. [68] Champsaur, M., Lanier, L.L., Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235:1 (2010), 267–285.
69. [69] Wu, J., Song, Y., Bakker, A.B., Bauer, S., Spies, T., Lanier, L.L., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:5428 (1999), 730–732.
70. [70] Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A.M., Hsia, J.K., Vivier, E., et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3:12 (2002), 1142–1149.
71. [71] Garrity, D., Call, M.E., Feng, J., Wucherpfennig, K.W., The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 102:21 (2005), 7641–7646.
72. [72] Smyth, M.J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W.M., Hayakawa, Y., NKG2D function protects the host from tumor initiation. J Exp Med 202:5 (2005), 583–588.
73. [73] Raulet, D.H., Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:10 (2003), 781–790.
74. [74] Romagne, F., Andre, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114:13 (2009), 2667–2677.
75. [75] Benson, D.M. Jr, Bakan, C.E., Zhang, S., Collins, S.M., Liang, J., Srivastava, S., et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118:24 (2011), 6387–6391.
76. [76] Ruggeri, L., Urbani, E., Andre, P., Mancusi, A., Tosti, A., Topini, F., et al. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica 101:5 (2016), 626–633.
77. [77] Imamura, M., Shook, D., Kamiya, T., Shimasaki, N., Chai, S.M., Coustan-Smith, E., et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. Blood 124:7 (2014), 1081–1088.
78. [78] Rubnitz, J.E., Inaba, H., Ribeiro, R.C., Pounds, S., Rooney, B., Bell, T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:6 (2010), 955–959.
79. [79] Torikai, H., Reik, A., Soldner, F., Warren, E.H., Yuen, C., Zhou, Y., et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122:8 (2013), 1341–1349.
80. [80] Valton, J., Guyot, V., Marechal, A., Filhol, J.M., Juillerat, A., Duclert, A., et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol Ther 23:9 (2015), 1507–1518.
81. [81] Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14:7 (2012), 830–840.
82. [82] Li, L., Liu, L.N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J., et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 17:3 (2010), 147–154.
83. [83] Shimasaki, N., Campana, D., Natural killer cell reprogramming with chimeric immune receptors. Methods Mol Biol 969 (2013), 203–220.
84. [84] Kruschinski, A., Moosmann, A., Poschke, I., Norell, H., Chmielewski, M., Seliger, B., et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci USA 105:45 (2008), 17481–17486.
85. [85] Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 15:15 (2009), 4857–4866.
86. [86] Wiernik, A., Foley, B., Zhang, B., Verneris, M.R., Warlick, E., Gleason, M.K., et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res 19:14 (2013), 3844–3855.
87. [87] Vallera, D.A., Zhang, B., Gleason, M.K., Oh, S., Weiner, L.M., Kaufman, D.S., et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm 28:4 (2013), 274–282.
88. [88] Szmania, S., Lapteva, N., Garg, T., Greenway, A., Lingo, J., Nair, B., et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 38:1 (2015), 24–36.
89. [89] Garg, T.K., Szmania, S.M., Khan, J.A., Hoering, A., Malbrough, P.A., Moreno-Bost, A., et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 97:9 (2012), 1348–1356.
90. [90] Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:5594 (2002), 850–854.
91. [91] Hamelik, R.M., Krishan, A., Click-iT assay with improved DNA distribution histograms. Cytometry A 75:10 (2009), 862–865.
92. [92] Hank, J.A., Surfus, J., Gan, J., Albertini, M., Lindstrom, M., Schiller, J.H., et al. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin Cancer Res 5:2 (1999), 281–289.